arsenic trioxide has been researched along with Neoplasms in 71 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (1.41) | 18.7374 |
| 1990's | 2 (2.82) | 18.2507 |
| 2000's | 25 (35.21) | 29.6817 |
| 2010's | 26 (36.62) | 24.3611 |
| 2020's | 17 (23.94) | 2.80 |
| Authors | Studies |
|---|---|
| Kouchak, M; Mahdavinia, M; Mirveis, Z; Rahbar, N | 1 |
| Dobson, R; Essa, H; Lip, GYH | 1 |
| Agrawal, Y; Gupta, NA; Manne, RK; Nadkarni, KS; Santra, MK | 1 |
| Chen, H; Deng, Y; Guo, M; Ke, H; Liu, M; Luo, J; Shen, J; Song, X; Sun, P; Wei, C; Yang, T; Zhai, Y | 1 |
| Chen, Y; Wang, J; Wu, W; Xue, X; Zheng, N | 1 |
| Begimbetova, D; Burska, AN; Dildabek, A; Ilyassova, B; Khamijan, M; Molnár, F; Sarbassov, DD | 1 |
| Chen, J; Jin, Z; Li, P; Ma, Y; Yang, H; Zhang, S; Zhang, X | 1 |
| Chen, X; Dai, Y; Fang, H; Li, J; Li, Y; Liang, Y; Lu, M; Ma, Y; Song, H; Tang, Y; Wang, Z; Wu, J; Wu, L; Wu, W; Wu, Y; Xiang, X; Xiao, S; Xing, Y; Yan, N; Ye, C; Zhang, S; Zheng, D | 1 |
| Gavegnano, C; Marconi, VC; Owanikoko, T; Savarino, A | 1 |
| Hosokawa, Y; Ota, A; Wahiduzzaman, M | 1 |
| Fu, X; Li, YS; Liang, QR; Luo, RG; Tang, Q; Yu, LL; Zhao, J | 1 |
| Jiang, Y; Naranmandura, H; Wang, QQ | 1 |
| Cai, X; Fei, W; Li, C; Li, F; Song, Q; Tao, J; Yao, W; Yao, Y; Ye, Y; Zhang, Y; Zheng, C | 1 |
| De, SK; Maiti, S; Medda, N | 1 |
| Loh, SN | 1 |
| Cirri, D; Ferraro, G; Imbimbo, P; Maria Monti, D; Merlino, A; Messori, L; Pratesi, A | 1 |
| Bunzen, H; Kerl, K; Sönksen, M | 1 |
| Bhatt, P; Hoonjan, M; Jadhav, V | 1 |
| He, T; Yu, H; Yu, HQ; Yue, QX | 1 |
| Chen, CH; Chen, Y; Dhe-Paganon, S; Doctor, ZM; Gao, ZJ; Herbert, MK; Jackson, BP; Kozono, S; Lian, X; Lin, YM; Lu, KP; Massefski, W; Pinch, B; Qiu, C; Seo, HS; Tan, L; Zhou, XZ | 1 |
| Cai, X; Hu, G; Ni, X | 1 |
| Gao, J; Gong, X; Huang, J; Lin, H; Luo, X; Shan, H; Xin, J; Yang, Z; Zhang, K | 1 |
| Bunzen, H; Ettlinger, R; Kerl, K; Moreno, N; Volkmer, D | 1 |
| Bradley, TP; Budman, DR; Kritharis, A | 1 |
| Berger, W; Ferk, F; Heffeter, P; Hoda, MA; Jungwirth, U; Karnthaler-Benbakka, C; Knasmüller, S; Kowol, CR; Kryeziu, K | 1 |
| Hoffman, E; Mielicki, WP | 1 |
| Chen, Y; Li, P; Tong, N; Yang, S; Zhang, J; Zhao, X | 1 |
| Ardalan, B; Subbarayan, PR | 1 |
| Cheng, YL; Huang, HS; Liu, ZM; Tseng, HY; Wu, WJ; Yeh, BW | 1 |
| Berger, W; Cichna-Markl, M; Englinger, B; Grillari, J; Heffeter, P; Körner, W; Kryeziu, K; Mohr, T; Pirker, C; Spitzwieser, M; Tav, K; van Schoonhoven, S; Weinmüllner, R | 1 |
| Grzanka, A; Izdebska, M; Litwiniec, A; Szczepański, MA | 1 |
| Platanias, LC | 1 |
| D'Andrea, DM; Darwish, M; Porter, JM; Remick, SC; Sweeney, CJ; Takimoto, C; Tracewell, WG; Wood, L | 1 |
| Bachleitner-Hofmann, T; Roth, E; Sturlan, S; Wessner, B; Wirtitsch, M | 1 |
| Efferth, T; Hoheisel, JD; Youns, M | 1 |
| Tallman, MS | 1 |
| Murphy, RK; O'Halloran, TV; Schatz, GC; Winter, ND | 1 |
| Da Sacco, L; Masotti, A | 1 |
| Gibson, SB | 1 |
| Cheng, IC; Lee, TC; Shue, JJ; Wang, TC | 1 |
| Raju, GP | 1 |
| Chen, X; Cho, SJ; Liu, S; Yan, W; Zhang, J; Zhang, Y | 1 |
| Couchman, IMS; Ive, EC; Reddy, L | 1 |
| Knox, SJ; Li, X; Nolley, R; Peehl, DM; Reese, SW; Tian, J; Young, SR; Zhao, H | 1 |
| Barbey, JT; Pezzullo, JC; Soignet, SL | 1 |
| Hori, S; Kakehi, Y; Kakizuka, A; Maeda, H; Ogawa, O; Ohizumi, H; Segawa, T | 1 |
| Bachleitner-Hofmann, T; Baumgartner, M; Roth, E; Sturlan, S; Wessner, B | 1 |
| Chen, YY; Guo, QS; Hu, QS; Kang, XL; Li, H; Lu, Y; Shi, GY; Tang, XM; Wang, XJ; Yang, J; Yi, J | 1 |
| An, S; Gwak, HS; Hong, SI; Jin, HO; Lee, HC; Lee, SJ; Park, IC; Park, MJ; Rhee, CH; Woo, SH | 1 |
| Griffin, RJ; Park, HJ; Song, CW; Williams, BW | 1 |
| Brown, SL; Kim, JH; Kolozsvary, A | 1 |
| Engel, RH; Evens, AM | 1 |
| Au, WY; Chan, EY; Cheng, VC; Kumana, CR; Kwong, YL; Lam, CW; Liu, R; Shek, TW | 1 |
| Chen, Y; Hu, Q; Jing, Y; Li, H; Shi, G; Tang, X; Wang, Y; Yang, J; Yi, J | 1 |
| Brdiczka, D; Israelson, A; Sheu, SS; Shoshan-Barmatz, V | 1 |
| Ewer, MS; Jones, RL | 1 |
| Chung, HY; Kang, YH; Kim, CH; Lee, SJ; Lee, YS; Park, IC; Park, MT | 1 |
| Bai, J; Chen, H; Chen, R; Li, A; Liu, Z; Mao, W; Ye, J; Zhou, J | 1 |
| Ahn, WS; Bae, IJ; Bae, SM; Chang, HS; Kim, CK; Kim, YW; Kwak, SY; Lee, YJ; Min, HJ; Shin, JC | 1 |
| Chew, EH; Holmgren, A; Lu, J | 1 |
| Cao, WJ; Li, Q; Wang, Y | 1 |
| Bae, JH; Chung, BS; Kang, CD; Kim, JY; Kim, SH; Lee, EY; Lee, SH | 1 |
| Miller, M | 1 |
| Cheson, BD; McBee, WL; Murgo, AJ | 1 |
| Warrell, RP | 1 |
| Cotter, FE; Fennell, DA | 1 |
| Antman, KH | 1 |
| Chen, GQ; Chen, SJ; Chen, Z; Shen, ZX; Sun, GL; Tong, JH; Wang, ZY | 1 |
| Aoyama, H; Harada, M; Hotta, N; Kurumatani, N; Nagira, T; Tsuda, T; Yamamoto, M | 1 |
| Durães, F; Maia, M; Pinto, MMM; Resende, DISP; Sousa, E | 1 |
| Brukštus, A; Čikotienė, I; Kairys, V; Karpavičienė, I; Lebedytė, I; Navakauskienė, R; Raškevičius, V; Valiulienė, G | 1 |
28 review(s) available for arsenic trioxide and Neoplasms
| Article | Year |
|---|---|
Chemotherapy-Induced Arrhythmias.
Topics: Anticoagulants; Antineoplastic Agents; Arsenic Trioxide; Atrial Fibrillation; Electrocardiography; Humans; Neoplasms; Protein Kinase Inhibitors | 2022 |
Targeting prolyl isomerase Pin1 as a promising strategy to overcome resistance to cancer therapies.
Topics: Antineoplastic Agents; Arsenic Trioxide; beta Catenin; Humans; Mitogen-Activated Protein Kinase Kinases; Neoplasms; NF-kappa B; NIMA-Interacting Peptidylprolyl Isomerase; Peptidylprolyl Isomerase; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Tretinoin | 2022 |
Enhancing an Oxidative "Trojan Horse" Action of Vitamin C with Arsenic Trioxide for Effective Suppression of KRAS-Mutant Cancers: A Promising Path at the Bedside.
Topics: Arsenic Trioxide; Ascorbic Acid; Cell Line, Tumor; Humans; Neoplasms; Oxidation-Reduction; Oxidative Stress; Proto-Oncogene Proteins p21(ras); Reactive Oxygen Species; Vitamins | 2022 |
Crossroads of Cancer and HIV-1: Pathways to a Cure for HIV.
Topics: Arsenic Trioxide; B7-H1 Antigen; Hematopoietic Stem Cell Transplantation; HIV Infections; Humans; Janus Kinases; Neoplasms; Programmed Cell Death 1 Receptor; Thioredoxin-Disulfide Reductase | 2019 |
Novel Mechanistic Insights into the Anti-cancer Mode of Arsenic Trioxide.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Female; Hematologic Neoplasms; Humans; Male; Neoplasms | 2020 |
Will Arsenic Trioxide Benefit Treatment of Solid Tumor by Nano- Encapsulation?
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Clinical Trials as Topic; Drug Carriers; Drug Compounding; Humans; Nanomedicine; Nanoparticles; Neoplasms; Tissue Distribution; Treatment Outcome | 2020 |
Therapeutic strategy of arsenic trioxide in the fight against cancers and other diseases.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Arsenic Trioxide; Humans; Leukemia, Promyelocytic, Acute; Neoplasms; Virus Diseases | 2020 |
Construction of arsenic-metal complexes loaded nanodrugs for solid tumor therapy: A mini review.
Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Drug Compounding; Humans; Lipids; Liposomes; Nanoparticles; Neoplasms; Transition Elements; Tumor Microenvironment | 2020 |
Different mechanisms of arsenic related signaling in cellular proliferation, apoptosis and neo-plastic transformation.
Topics: Antineoplastic Agents; Apoptosis; Arsenic; Arsenic Trioxide; Arsenicals; Cell Proliferation; Humans; Mitochondria; Mitogen-Activated Protein Kinases; Neoplasms; Oxides; Plastics; Signal Transduction | 2021 |
Current status and future prospects of nanomedicine for arsenic trioxide delivery to solid tumors.
Topics: Antineoplastic Agents; Arsenic Trioxide; Humans; Nanomedicine; Nanoparticles; Neoplasms | 2022 |
Arsenic trioxide: insights into its evolution to an anticancer agent.
Topics: Antineoplastic Agents; Arsenic Trioxide; Carcinogens; Humans; Neoplasms | 2018 |
[Research progress on anti-cancer mechanisms of arsenic trioxide and artemisinin].
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Artemisinins; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Gene Expression Regulation, Neoplastic; Humans; MicroRNAs; Neoplasms; Oxides; Signal Transduction | 2016 |
The success and the challenge of all-trans retinoic acid in the treatment of cancer.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Cell Differentiation; Cell Proliferation; Drug Therapy; Humans; Leukemia, Promyelocytic, Acute; Neoplasms; Receptors, Retinoic Acid; Signal Transduction; Tretinoin | 2019 |
The evolving use of arsenic in pharmacotherapy of malignant disease.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Poisoning; Arsenic Trioxide; Arsenicals; Biotransformation; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Gastrointestinal Diseases; Gene Expression Regulation; Heart Diseases; Humans; Leukemia, Promyelocytic, Acute; Leukocytosis; Metabolic Networks and Pathways; Methyltransferases; Neoplasms; Oxides; Reactive Oxygen Species; Signal Transduction; Treatment Outcome | 2013 |
[Arsenic trioxide: impact on the growth and differentiation of cancer cells and possible use in cancer therapy].
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Arsenic Trioxide; Arsenicals; Caspases; Cell Differentiation; Cell Line, Tumor; Drug Resistance, Neoplasm; Humans; Leukemia, Promyelocytic, Acute; MAP Kinase Kinase 4; Mitochondria; Neoplasms; NF-kappa B; Oxides | 2013 |
In the war against solid tumors arsenic trioxide needs partners.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; Brain Diseases; Clinical Trials as Topic; Combined Modality Therapy; Drug Approval; Drug Synergism; Hedgehog Proteins; Hematologic Diseases; Humans; Medicine, Chinese Traditional; Neoplasm Proteins; Neoplasms; Oncogene Proteins, Fusion; Oxides; Radiotherapy, Adjuvant; Signal Transduction; Thymidylate Synthase; Transcription Factors; Treatment Outcome; United States; United States Food and Drug Administration; Zinc Finger Protein GLI1 | 2014 |
[Selected mechanisms of the therapeutic effect of arsenic trioxide in cancer treatment].
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Caspases; Drug Therapy, Combination; Glutathione; Humans; Intercellular Signaling Peptides and Proteins; MAP Kinase Kinase 4; Neoplasms; NF-kappa B; Oxides; Tretinoin | 2008 |
Biological responses to arsenic compounds.
Topics: Antineoplastic Agents; Apoptosis; Arsenic; Arsenic Trioxide; Arsenicals; Cell Death; Cell Line, Tumor; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Models, Biological; Models, Chemical; Neoplasms; Oxides; Signal Transduction | 2009 |
Traditional Chinese medicines (TCMs) for molecular targeted therapies of tumours.
Topics: Animals; Antineoplastic Agents, Phytogenic; Arsenic Trioxide; Arsenicals; Artemisinins; Artesunate; Berberine; Biological Products; Cantharidin; Complementary Therapies; Curcumin; Drug Delivery Systems; Drug Screening Assays, Antitumor; Drugs, Chinese Herbal; Humans; Medicine, Chinese Traditional; Models, Biological; Neoplasms; Oxides | 2010 |
Chitin and chitosan as multipurpose natural polymers for groundwater arsenic removal and AS2O3 delivery in tumor therapy.
Topics: Arsenates; Arsenic; Arsenic Trioxide; Arsenicals; Arsenites; Chitin; Chitosan; Drug Carriers; Humans; Nanotechnology; Neoplasms; Oxides; Polymers; Water Pollutants, Chemical; Water Purification | 2010 |
Oxidative stress and apoptosis: a new treatment paradigm in cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Buthionine Sulfoximine; Cell Death; Dose-Response Relationship, Drug; Glutathione; Hexanones; Humans; Metalloporphyrins; Models, Biological; Models, Chemical; Neoplasms; Oxidation-Reduction; Oxidative Stress; Oxides; Reactive Oxygen Species | 2006 |
The voltage-dependent anion channel (VDAC): function in intracellular signalling, cell life and cell death.
Topics: Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; bcl-2-Associated X Protein; Calcium; Cytochromes c; Humans; Ion Channel Gating; Mitochondria; Mitochondrial Membranes; Models, Molecular; Neoplasms; Oxides; Permeability; Protein Conformation; Protein Folding; Protein Isoforms; Proto-Oncogene Proteins c-bcl-2; Ruthenium Red; Signal Transduction; Voltage-Dependent Anion Channels | 2006 |
Cardiac and cardiovascular toxicity of nonanthracycline anticancer drugs.
Topics: Anthracyclines; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cardiovascular Diseases; Heart Diseases; Humans; Interferons; Interleukin-2; Neoplasms; Oxides; Stilbenes; Tretinoin | 2006 |
[Research advance of nanometric traditional Chinese herbal drugs for cancer treatment].
Topics: Arsenic Trioxide; Arsenicals; Camptothecin; Drug Carriers; Drugs, Chinese Herbal; Humans; Nanoparticles; Nanotechnology; Neoplasms; Oxides | 2007 |
Arsenicals and inhibitors of histone deacetylase as anticancer therapy.
Topics: Acetylation; Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Child; China; Chromatin; Drug Evaluation; Drug Resistance, Neoplasm; Enzyme Inhibitors; Gastrointestinal Diseases; Histone Deacetylase Inhibitors; Humans; Leukemia, Promyelocytic, Acute; Leukocytosis; Melarsoprol; Neoplasm Proteins; Neoplasms; Nervous System Diseases; Oxides; Phenylbutyrates; Protein Processing, Post-Translational; Salvage Therapy; Tretinoin | 1999 |
Controlling the mitochondrial gatekeeper for effective chemotherapy.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; GABA-A Receptor Antagonists; Gene Expression Regulation; Genes, bcl-2; Humans; Intracellular Membranes; Isoquinolines; Mitochondria; Neoplasms; Oligonucleotides, Antisense; Oxides; Protoporphyrins | 2000 |
Expanding the use of arsenic trioxide: leukemias and beyond.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Humans; Leukemia; Leukemia, Promyelocytic, Acute; Multiple Myeloma; Neoplasms; Oxides | 2002 |
Xanthenes in Medicinal Chemistry - Synthetic strategies and biological activities.
Topics: Anti-Infective Agents; Antineoplastic Agents; Bacteria; Chemistry, Pharmaceutical; Fungi; Humans; Neoplasms; Neuroprotective Agents; Xanthenes | 2021 |
43 other study(ies) available for arsenic trioxide and Neoplasms
| Article | Year |
|---|---|
Novel and efficient method for loading aptamer-conjugated liposomes with arsenic trioxide for targeting cancer cells.
Topics: Antineoplastic Agents; Arsenic Trioxide; Drug Delivery Systems; Liposomes; Neoplasms; Spectroscopy, Fourier Transform Infrared | 2022 |
F-box protein FBXO41 plays vital role in arsenic trioxide-mediated autophagic death of cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Autophagic Cell Death; Cell Line, Tumor; F-Box Proteins; Humans; Neoplasms; Oxides | 2022 |
Self-activated arsenic manganite nanohybrids for visible and synergistic thermo/immuno-arsenotherapy.
Topics: Albumins; Antineoplastic Agents; Apoptosis; Arsenic; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Glutathione; Humans; Immune Checkpoint Inhibitors; Manganese; Manganese Compounds; Neoplasms; Oxides; Protons; Tumor Microenvironment | 2022 |
Arsenic trioxide elicits prophylactic and therapeutic immune responses against solid tumors by inducing necroptosis and ferroptosis.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cancer Vaccines; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Ferroptosis; Humans; Immunity; Necroptosis; Neoplasms; Oxides | 2023 |
Diverse rescue potencies of p53 mutations to ATO are predetermined by intrinsic mutational properties.
Topics: Animals; Apoptosis; Arsenic Trioxide; Humans; Mice; Mutation; Neoplasms; Tumor Suppressor Protein p53 | 2023 |
Arsenic and an Old Place: Rescuing p53 Mutants in Cancer.
Topics: Arsenic; Arsenic Trioxide; Humans; Mutation; Neoplasms; Tumor Suppressor Protein p53 | 2021 |
Arsenoplatin-Ferritin Nanocage: Structure and Cytotoxicity.
Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; BALB 3T3 Cells; Cisplatin; Cytotoxins; Ferritins; Humans; Mice; Molecular Structure; Neoplasms; Platinum Compounds; Structure-Activity Relationship | 2021 |
Arsenic targets Pin1 and cooperates with retinoic acid to inhibit cancer-driving pathways and tumor-initiating cells.
Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Cell Proliferation; Female; Fibroblasts; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Leukemia, Promyelocytic, Acute; Magnetic Resonance Spectroscopy; Mice; Mice, Inbred BALB C; Mice, Knockout; Neoplasm Transplantation; Neoplasms; NIMA-Interacting Peptidylprolyl Isomerase; Proteomics; Signal Transduction; Tretinoin | 2018 |
Facile synthesis of aquo-cisplatin arsenite multidrug nanocomposites for overcoming drug resistance and efficient combination therapy.
Topics: Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenites; Cell Line, Tumor; Cisplatin; DNA Damage; Drug Resistance, Neoplasm; Humans; Male; Mice, Inbred BALB C; Nanocomposites; Neoplasms; Transcriptome | 2018 |
Zeolitic Imidazolate Framework-8 as pH-Sensitive Nanocarrier for "Arsenic Trioxide" Drug Delivery.
Topics: Arsenic Trioxide; Drug Delivery Systems; Hydrogen-Ion Concentration; Nanoparticles; Neoplasms; Polyethylene Glycols; Zeolites | 2019 |
Synergistic anticancer activity of arsenic trioxide with erlotinib is based on inhibition of EGFR-mediated DNA double-strand break repair.
Topics: Acid Anhydride Hydrolases; Animals; Arsenic Trioxide; Arsenicals; BRCA1 Protein; DNA Breaks, Double-Stranded; DNA Repair; DNA Repair Enzymes; DNA-Binding Proteins; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Humans; Mice; Neoplasms; Oxides; Phosphorylation; Quinazolines; Rad51 Recombinase; Signal Transduction; Xenograft Model Antitumor Assays | 2013 |
Tetrandrine enhances the anticancer effects of arsenic trioxide in vitro.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; Benzylisoquinolines; Cell Cycle Checkpoints; Cell Proliferation; Dose-Response Relationship, Drug; Drug Synergism; HeLa Cells; Hep G2 Cells; Humans; Necrosis; Neoplasms; Oxides; Time Factors | 2014 |
TG-interacting factor transcriptionally induced by AKT/FOXO3A is a negative regulator that antagonizes arsenic trioxide-induced cancer cell apoptosis.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Binding Sites; Cell Movement; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p21; Dose-Response Relationship, Drug; Forkhead Box Protein O3; Forkhead Transcription Factors; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Homeodomain Proteins; Humans; JNK Mitogen-Activated Protein Kinases; MCF-7 Cells; Neoplasm Invasiveness; Neoplasms; Oxides; Phosphorylation; Promoter Regions, Genetic; Proto-Oncogene Proteins c-akt; Repressor Proteins; Signal Transduction; Transcription, Genetic; Transfection | 2015 |
Chronic arsenic trioxide exposure leads to enhanced aggressiveness via Met oncogene addiction in cancer cells.
Topics: Animals; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Cell Proliferation; Crizotinib; Drug Resistance, Neoplasm; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; HCT116 Cells; Humans; Mice, SCID; Neoplasms; Oxides; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Pyrazoles; Pyridines; RNA Interference; Xenograft Model Antitumor Assays | 2016 |
A pharmacokinetic and safety study of intravenous arsenic trioxide in adult cancer patients with renal impairment.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Area Under Curve; Arsenic Trioxide; Arsenicals; Biotransformation; Female; Humans; Karnofsky Performance Status; Kidney Diseases; Male; Methylation; Middle Aged; Neoplasms; Oxides | 2010 |
Omega-3 and omega-6 polyunsaturated fatty acids enhance arsenic trioxide efficacy in arsenic trioxide-resistant leukemic and solid tumor cells.
Topics: Antineoplastic Agents; Apoptosis; Arachidonic Acid; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Fatty Acids, Omega-3; Fatty Acids, Omega-6; Humans; Leukemia; Lipid Peroxidation; Neoplasms; Oxides; Vitamin E | 2009 |
All-trans retinoic acid and arsenic rescue patients with acute promyelocytic leukemia from a potential 'perfect storm'.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Neoplasms; Oxides; Prognosis; Tretinoin | 2010 |
Development and modeling of arsenic-trioxide-loaded thermosensitive liposomes for anticancer drug delivery.
Topics: 1,2-Dipalmitoylphosphatidylcholine; Arsenic Trioxide; Arsenicals; Calorimetry, Differential Scanning; Gels; Humans; Lipid Bilayers; Liposomes; Molecular Dynamics Simulation; Neoplasms; Oxides; Permeability; Phase Transition; Phosphatidylcholines; Transition Temperature | 2011 |
A matter of balance between life and death: targeting reactive oxygen species (ROS)-induced autophagy for cancer therapy.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Autophagy; Cell Line, Tumor; Humans; Mercaptoethanol; Neoplasms; Oxidative Stress; Oxides; Reactive Oxygen Species | 2010 |
Cytotoxicity of arsenic trioxide is enhanced by (-)-epigallocatechin-3-gallate via suppression of ferritin in cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Caffeic Acids; Catechin; Cell Line, Tumor; Cytotoxins; Drug Synergism; Ferritins; Heme Oxygenase (Decyclizing); HL-60 Cells; Humans; Neoplasms; Oxides; Phenylethyl Alcohol | 2011 |
Arsenic: a potentially useful poison for Hedgehog-driven cancers.
Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Hedgehog Proteins; Humans; Medulloblastoma; Mice; Models, Biological; Neoplasms; Oxides; Receptors, G-Protein-Coupled; Sarcoma, Ewing; Signal Transduction; Smoothened Receptor; Transcription Factors; Zinc Finger Protein GLI1 | 2011 |
Mutant p53 protein is targeted by arsenic for degradation and plays a role in arsenic-mediated growth suppression.
Topics: Antineoplastic Agents; Arsenic; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Cell Survival; Humans; Neoplasms; Nuclear Proteins; Oxidative Stress; Oxides; Promyelocytic Leukemia Protein; Proteasome Endopeptidase Complex; Transcription Factors; Tumor Suppressor Protein p53; Tumor Suppressor Proteins | 2011 |
Therapeutic effect of Arsenicum album on leukocytes.
Topics: Arsenic Trioxide; Arsenicals; Cell Line, Transformed; Cell Survival; Dose-Response Relationship, Drug; Homeopathy; Humans; Leukocytes; Neoplasms; Oxides | 2012 |
Darinaparsin: solid tumor hypoxic cytotoxin and radiosensitizer.
Topics: Animals; Apoptosis; Arsenic Trioxide; Arsenicals; Bone Marrow; Cell Hypoxia; Glutathione; Humans; Intestines; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasms; Oxides; Proto-Oncogene Proteins c-myc; Proto-Oncogene Proteins p21(ras); Radiation-Sensitizing Agents; Reactive Oxygen Species; Xenograft Model Antitumor Assays | 2012 |
Effect of arsenic trioxide on QT interval in patients with advanced malignancies.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Child; Child, Preschool; Clinical Trials as Topic; Electrocardiography; Female; Humans; Leukemia, Promyelocytic, Acute; Long QT Syndrome; Male; Middle Aged; Neoplasms; Oxides; Retrospective Studies; Torsades de Pointes | 2003 |
Effective treatment of advanced solid tumors by the combination of arsenic trioxide and L-buthionine-sulfoximine.
Topics: Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Buthionine Sulfoximine; Cell Division; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Interactions; Drug Resistance, Neoplasm; Drug Therapy, Combination; Female; Glutathione; HeLa Cells; Humans; Hydrogen Peroxide; Male; Mice; Neoplasm Metastasis; Neoplasm Transplantation; Neoplasms; Oxides; Prostatic Neoplasms; Reactive Oxygen Species; Transplantation, Heterologous; Xenograft Model Antitumor Assays | 2004 |
Enhancement of arsenic trioxide-mediated apoptosis using docosahexaenoic acid in arsenic trioxide-resistant solid tumor cells.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Docosahexaenoic Acids; Drug Interactions; Drug Resistance, Neoplasm; Humans; Neoplasms; Oxides; Reactive Oxygen Species; Tumor Cells, Cultured | 2004 |
Anthraquinones sensitize tumor cells to arsenic cytotoxicity in vitro and in vivo via reactive oxygen species-mediated dual regulation of apoptosis.
Topics: Animals; Anthraquinones; Antioxidants; Apoptosis; Arsenic Trioxide; Arsenicals; Caspase 3; Caspase 9; Caspases; Cell Line, Tumor; Cytochromes c; Emodin; Enzyme Activation; Humans; Intracellular Membranes; Mice; Mitochondria; Neoplasm Transplantation; Neoplasms; NF-kappa B; Oxides; Phorbol Esters; Reactive Oxygen Species; Signal Transduction | 2004 |
Diarsenic and tetraarsenic oxide inhibit cell cycle progression and bFGF- and VEGF-induced proliferation of human endothelial cells.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Proliferation; Cells, Cultured; Dose-Response Relationship, Drug; Endothelial Cells; Fibroblast Growth Factor 2; Humans; Neoplasms; Oxides; Vascular Endothelial Growth Factor A | 2005 |
Preferential action of arsenic trioxide in solid-tumor microenvironment enhances radiation therapy.
Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Carbon Dioxide; Endothelial Cells; Enzyme Activation; Female; Hydrogen-Ion Concentration; JNK Mitogen-Activated Protein Kinases; Mice; Mice, Inbred C3H; Neoplasms; Oxides; Oxygen; Oxygen Consumption; Partial Pressure; Radiation-Sensitizing Agents; Regional Blood Flow | 2005 |
Vascular targeting therapies for treatment of malignant disease.
Topics: Angiogenesis Inhibitors; Arsenic Trioxide; Arsenicals; Clinical Trials as Topic; Humans; Neoplasms; Oxides | 2005 |
Solid tumors subsequent to arsenic trioxide treatment for acute promyelocytic leukemia.
Topics: Adenocarcinoma; Adult; Aged; Arsenic Trioxide; Arsenicals; Colonic Neoplasms; Female; Growth Inhibitors; Humans; Leukemia, Promyelocytic, Acute; Male; Nasopharyngeal Neoplasms; Neoplasms; Oxides | 2007 |
Alteration of subcellular redox equilibrium and the consequent oxidative modification of nuclear factor kappaB are critical for anticancer cytotoxicity by emodin, a reactive oxygen species-producing agent.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Nucleus; DNA, Neoplasm; Emodin; HeLa Cells; Humans; I-kappa B Proteins; Neoplasms; NF-kappa B; NF-kappa B p50 Subunit; Oxidants; Oxidation-Reduction; Oxidative Stress; Oxides; Protein Transport; Reactive Oxygen Species; Transcription Factor RelA; Tumor Necrosis Factor-alpha | 2006 |
Combination treatment with arsenic trioxide and phytosphingosine enhances apoptotic cell death in arsenic trioxide-resistant cancer cells.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; bcl-2-Associated X Protein; Drug Resistance, Neoplasm; Enzyme Activation; Humans; Mitochondria; Models, Biological; Neoplasms; Oxides; p38 Mitogen-Activated Protein Kinases; Poly(ADP-ribose) Polymerases; Protein Transport; Reactive Oxygen Species; Sphingosine | 2007 |
JWA as a functional molecule to regulate cancer cells migration via MAPK cascades and F-actin cytoskeleton.
Topics: Actins; Amino Acid Motifs; Amino Acid Sequence; Arsenic Trioxide; Arsenicals; Base Sequence; Cell Movement; Cyclooxygenase 2; Cytoskeleton; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; Focal Adhesion Kinase 1; Heat-Shock Proteins; HeLa Cells; Humans; Intracellular Signaling Peptides and Proteins; MAP Kinase Kinase 1; MAP Kinase Signaling System; Membrane Transport Proteins; Mitogen-Activated Protein Kinases; Molecular Sequence Data; Neoplasms; Oxides; Phosphorylation; Protein Kinase C; Tetradecanoylphorbol Acetate | 2007 |
Comparison of diarsenic oxide and tetraarsenic oxide on anticancer effects: relation to the apoptosis molecular pathway.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Separation; Drug Screening Assays, Antitumor; Flow Cytometry; Humans; Neoplasms; Oxides; Proliferating Cell Nuclear Antigen; Proto-Oncogene Proteins c-bcl-2 | 2007 |
Targeting thioredoxin reductase is a basis for cancer therapy by arsenic trioxide.
Topics: Amino Acid Sequence; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Cell Survival; Enzyme Inhibitors; Glutathione; Humans; Molecular Sequence Data; Neoplasms; Oxidation-Reduction; Oxides; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Thioredoxin-Disulfide Reductase | 2007 |
Induction of NKG2D ligands and subsequent enhancement of NK cell-mediated lysis of cancer cells by arsenic trioxide.
Topics: Arsenic Trioxide; Arsenicals; Cell Death; Cell Line, Tumor; Cell Membrane; Down-Regulation; Gene Expression Regulation, Neoplastic; Humans; Killer Cells, Natural; Ligands; Neoplasms; NK Cell Lectin-Like Receptor Subfamily K; Oxides; Receptors, Immunologic; Receptors, Natural Killer Cell; Up-Regulation | 2008 |
Scientists explore use of arsenic in therapy.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Promyelocytic, Acute; Neoplasms; Oxides | 1998 |
Clinical trials referral resource. Clinical trials with arsenic trioxide.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Clinical Trials as Topic; Female; Humans; Leukemia; Lymphoma; Multiple Myeloma; Neoplasms; Oxides; Urogenital Neoplasms; Uterine Cervical Neoplasms | 2000 |
Introduction: the history of arsenic trioxide in cancer therapy.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; History, 18th Century; History, 19th Century; History, 20th Century; Humans; Neoplasms; Oxides | 2001 |
Malignant neoplasms among residents who drank well water contaminated by arsenic from a king's yellow factory.
Topics: Adult; Aged; Arsenic; Arsenic Poisoning; Arsenic Trioxide; Arsenicals; Chemical Industry; Child; Cohort Studies; Drinking; Female; Humans; Japan; Lung Neoplasms; Male; Middle Aged; Neoplasms; Neoplasms, Multiple Primary; Oxides; Retrospective Studies; Smoking; Sulfides; Water Pollution, Chemical; Water Supply | 1989 |
Synthesis and antiproliferative activity of α-branched α,β-unsaturated ketones in human hematological and solid cancer cell lines.
Topics: Cell Line, Tumor; Cell Proliferation; Hematologic Neoplasms; Humans; Ketones; Neoplasms; Quantitative Structure-Activity Relationship | 2015 |